Loading
NASDAQHealthcareBiotechnology
Latest quote
$23.17
−$0.17 · -0.73%
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Previous close
$23.17
−$0.17 · -0.73%
Regular session · ET · Market data may be delayed.
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Day range
Current $23.17
52-week range
Current $23.17
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
55
Mixed
Risk
35
Moderate Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Day range
Current $23.17
52-week range
Current $23.17
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | 125.1M USD | 63.62M USD | 30.62M USD | 31.31M USD |
| Selling, general, and administrative | 30.51M USD | 18.77M USD | 9.27M USD | 6.34M USD |
| Operating expenses | 155.6M USD | 82.39M USD | 39.89M USD | 37.66M USD |
| Interest income | 17.87M USD | 14.58M USD | 1.31M USD | 4K USD |
| Interest expense | — | — | — | 112K USD |
| Depreciation and amortization | 105K USD | 56K USD | 19K USD | 10K USD |
| Operating income | −155.6M USD | −82.39M USD | −39.89M USD | −37.66M USD |
| Net income | −137.95M USD | −68M USD | −51.99M USD | −37.85M USD |
Company facts updated Sep 7, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$32.57
40.57% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI45.44M0.00%2.3T USD0.03%$379.73-0.32%
State Street SPDR S&P Biotech ETFXBI27.29M0.24%11.49B USD0.35%$163.81-0.35%
iShares Russell 2000 ETFIWM26.42M0.03%80.51B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF13.33M0.01%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Growth ETFIWO8.42M0.06%14.7B USD0.24%$377.54+0.12%
Vanguard Russell 2000 ETFVTWO6.72M0.04%17.4B USD0.06%$119.62+0.25%
iShares Biotechnology ETFIBB6.63M0.06%10.73B USD0.44%$211.92-0.88%
Schwab U.S. Small-Cap ETFSCHA4.67M0.02%22.56B USD0.03%$34.55+1.01%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
